SILO
Silo Pharma, Inc.
Biotechnology
Market Cap$2M
5Y Perf.+20.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SILO vs PSTV
Revenue, margins, valuation, and 5-year total return — side by side.
PSTV
Plus Therapeutics, Inc.
Biotechnology
Market Cap$14M
5Y Perf.-99.3%
SILO vs PSTV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SILO | PSTV |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $2M | $14M |
| Revenue (TTM) | $72K | $5M |
| Net Income (TTM) | $-5M | $-22M |
| Gross Margin | -8.1% | 91.5% |
| Operating Margin | -74.5% | -293.5% |
| Total Debt | $0.00 | $821K |
| Cash & Equiv. | $4M | $9M |
SILO vs PSTV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SILO
PSTV
| Stock | Jan 21 | May 26 | Return |
|---|---|---|---|
| Silo Pharma, Inc. (SILO) | 100 | 120.3 | +20.3% |
| Plus Therapeutics, … (PSTV) | 100 | 0.7 | -99.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SILO vs PSTV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SILO leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Plus Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
SILO
Silo Pharma, Inc.
The Growth Play
SILO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 0.0%, EPS growth 0.8%, 3Y rev CAGR 0.4%
- 20.0% 10Y total return vs PSTV's -100.0%
- 0.0% revenue growth vs PSTV's -10.5%
Best for: growth exposure and long-term compounding
PSTV
Plus Therapeutics, Inc.
The Income Pick
PSTV is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 1.82
- Lower volatility, beta 1.82, Low D/E 20.5%, current ratio 1.23x
- Beta 1.82, current ratio 1.23x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SILO | 0.0% revenue growth vs PSTV's -10.5% |
| Quality / Margins | PSTV | -429.4% margin vs SILO's -70.4% |
| Stability / Safety | PSTV | Beta 1.82 vs SILO's 2.21 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SILO | -48.1% vs PSTV's -57.8% |
| Efficiency (ROA) | SILO | -79.5% ROA vs PSTV's -156.0% |
SILO vs PSTV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2022
SILO vs PSTV — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPSTVLAGGINGSILO
SILOSilo Pharma, Inc.
2leads
PSTVPlus Therapeutics, In…
3leads
6 Total Categories
CATEGORYLEADERvs SILOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PSTV5/6
Valuation MetricsMultiples, price ratios, and targets
PSTV2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SILO4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
SILO6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
PSTV1/1
Income & Cash Flow (Last 12 Months)
PSTV leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PSTV is the larger business by revenue, generating $5M annually — 72.3x SILO's $72,102. PSTV is the more profitable business, keeping -4.3% of every revenue dollar as net income compared to SILO's -70.4%. On growth, SILO holds the edge at 0.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SILOSilo Pharma, Inc. | PSTVPlus Therapeutics… |
|---|---|---|
| RevenueTrailing 12 months | $72,102 | $5M |
| EBITDAEarnings before interest/tax | -$5M | -$15M |
| Net IncomeAfter-tax profit | -$5M | -$22M |
| Free Cash FlowCash after capex | -$5M | -$21M |
| Gross MarginGross profit ÷ Revenue | -8.1% | +91.5% |
| Operating MarginEBIT ÷ Revenue | -74.5% | -2.9% |
| Net MarginNet income ÷ Revenue | -70.4% | -4.3% |
| FCF MarginFCF ÷ Revenue | -66.6% | -4.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | 0.0% | -3.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +45.5% | +100.0% |
PSTV leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
PSTV leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | SILOSilo Pharma, Inc. | PSTVPlus Therapeutics… |
|---|---|---|
| Market CapShares × price | $2M | $14M |
| Enterprise ValueMkt cap + debt − cash | -$2M | $6M |
| Trailing P/EPrice ÷ TTM EPS | -0.35x | -0.83x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 26.12x | 2.76x |
| Price / BookPrice ÷ Book value/share | 0.31x | 4.63x |
| Price / FCFMarket cap ÷ FCF | — | — |
PSTV leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
SILO leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
SILO delivers a -101.4% return on equity — every $100 of shareholder capital generates $-101 in annual profit, vs $-6 for PSTV. On the Piotroski fundamental quality scale (0–9), PSTV scores 4/9 vs SILO's 2/9, reflecting mixed financial health.
| Metric | SILOSilo Pharma, Inc. | PSTVPlus Therapeutics… |
|---|---|---|
| ROE (TTM)Return on equity | -101.4% | -5.6% |
| ROA (TTM)Return on assets | -79.5% | -156.0% |
| ROICReturn on invested capital | -186.7% | — |
| ROCEReturn on capital employed | -74.0% | -3.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | — | 0.21x |
| Net DebtTotal debt minus cash | -$4M | -$8M |
| Cash & Equiv.Liquid assets | $4M | $9M |
| Total DebtShort + long-term debt | $0 | $821,000 |
| Interest CoverageEBIT ÷ Interest expense | -1053.72x | -4.07x |
SILO leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
SILO leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SILO five years ago would be worth $16,471 today (with dividends reinvested), compared to $73 for PSTV. Over the past 12 months, SILO leads with a -48.1% total return vs PSTV's -57.8%. The 3-year compound annual growth rate (CAGR) favors SILO at -42.6% vs PSTV's -61.6% — a key indicator of consistent wealth creation.
| Metric | SILOSilo Pharma, Inc. | PSTVPlus Therapeutics… |
|---|---|---|
| YTD ReturnYear-to-date | +25.0% | -57.1% |
| 1-Year ReturnPast 12 months | -48.1% | -57.8% |
| 3-Year ReturnCumulative with dividends | -81.1% | -94.3% |
| 5-Year ReturnCumulative with dividends | +64.7% | -99.3% |
| 10-Year ReturnCumulative with dividends | +20.0% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -42.6% | -61.6% |
SILO leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SILO and PSTV each lead in 1 of 2 comparable metrics.
Risk & Volatility
PSTV is the less volatile stock with a 1.82 beta — it tends to amplify market swings less than SILO's 2.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SILO currently trades 37.2% from its 52-week high vs PSTV's 25.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SILOSilo Pharma, Inc. | PSTVPlus Therapeutics… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.21x | 1.82x |
| 52-Week HighHighest price in past year | $1.13 | $23.43 |
| 52-Week LowLowest price in past year | $0.22 | $0.27 |
| % of 52W HighCurrent price vs 52-week peak | +37.2% | +25.4% |
| RSI (14)Momentum oscillator 0–100 | 47.0 | 49.8 |
| Avg Volume (50D)Average daily shares traded | 4.6M | 355K |
Evenly matched — SILO and PSTV each lead in 1 of 2 comparable metrics.
Analyst Outlook
PSTV leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
| Metric | SILOSilo Pharma, Inc. | PSTVPlus Therapeutics… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +9.2% | 0.0% |
PSTV leads this category, winning 1 of 1 comparable metric.
Key Takeaway
PSTV leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). SILO leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallPlus Therapeutics, Inc. (PSTV)Leads 3 of 6 categories
Loading custom metrics...
SILO vs PSTV: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — SILO or PSTV?
Over the past 5 years, Silo Pharma, Inc.
(SILO) delivered a total return of +64. 7%, compared to -99. 3% for Plus Therapeutics, Inc. (PSTV). Over 10 years, the gap is even starker: SILO returned +20. 0% versus PSTV's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — SILO or PSTV?
By beta (market sensitivity over 5 years), Plus Therapeutics, Inc.
(PSTV) is the lower-risk stock at 1. 82β versus Silo Pharma, Inc. 's 2. 21β — meaning SILO is approximately 21% more volatile than PSTV relative to the S&P 500.
03Which is growing faster — SILO or PSTV?
On earnings-per-share growth, the picture is similar: Plus Therapeutics, Inc.
grew EPS 100. 0% year-over-year, compared to 0. 8% for Silo Pharma, Inc.. Over a 3-year CAGR, PSTV leads at 185. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — SILO or PSTV?
Plus Therapeutics, Inc.
(PSTV) is the more profitable company, earning -429. 4% net margin versus -60. 9% for Silo Pharma, Inc. — meaning it keeps -429. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PSTV leads at -293. 5% versus -65. 3% for SILO. At the gross margin level — before operating expenses — SILO leads at 91. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — SILO or PSTV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is SILO or PSTV better for a retirement portfolio?
For long-horizon retirement investors, Plus Therapeutics, Inc.
(PSTV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Silo Pharma, Inc. (SILO) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PSTV: -100. 0%, SILO: +20. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between SILO and PSTV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SILO: 0.0% · PSTV: -3.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.